AMENDMENTS TO THE CLAIMS:

This listing of claims will replace all prior versions, and listings, of claims in the application:

LISTING OF CLAIMS:

Claims 1. - 19. (Cancelled).

20. (previously presented) A cell composition, comprising:

macrophages present in an amount of about 10 to about 70%, said percentage is expressed with respect to the total number of cells;

and progenitor cells present in an amount of at least 0.1%, said percentage being expressed with respect to the total number of cells; and

wherein said composition exhibits anti-infectious and hematopoietic properties.

Claim 21. (cancelled).

22. (previously presented) The cell composition according to claim 20, wherein said progenitor cells are present in an amount of about 0.1 to about 20%, said percentage being expressed with respect to the total number of cells.

23. (previously presented) The cell composition according to claim 20, further comprising myeloid cells, said myeloid cells are present in an amount of about 10% to about 30%, said percentage being expressed with respect to the total number of cells.

Claims 24. - 25. (cancelled).

26. (previously presented) The cell composition according to claim 20, wherein said progenitor cells contain from about 0.1 to about 20% of stem cells, expressed with respect to the total number of progenitor cells.

27. (previously presented) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 20.

28. (currently amended) The cell composition according to claim 20, wherein said composition is derived from ~~and/or included in~~ a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,

- from about 1 to about 50% of polynuclear cells, and

- from about 0.1 to about 20% of stem cells.

Claims 29. - 31. (cancelled).

32. (previously presented) A cell composition comprising macrophages, myeloid cells and progenitor cells, said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages are in an amount of about 10 to about 70%, and said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- collecting mononuclear cells and progenitors by apheresis

- co-culturing blood mononuclear cells and progenitors, after washing of platelets, granulocytes and erythrocytes, for 4 to 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloid progenitors into polynuclear cells.

33. (previously presented) A cell composition comprising macrophages, myeloid cells and progenitor cells, wherein said progenitor cells are present in an amount of about 0.1% to about 20%, said macrophages being in an amount of about 10 to about 70%, said percentages are expressed with respect to the total number of cells, as obtained by a process comprising the following steps:

- mobilizing progenitor cells in the blood of a patient

by premedication of said patient with G-CSF and/or GM-CSF or G-CSF and cyclophosphamide,

- collecting mononuclear cells and progenitors by apheresis,

- co-culturing of the blood mononuclear cells and progenitors, after washing of platelets, granulocytes and erythrocytes, for 4 to 10 days, in a medium allowing differentiation of monocytes into macrophages and myeloid progenitors into polynuclear cells.

34. (previously presented) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 22.

35. (previously presented) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 23.

36. (previously presented) A composition comprising, a pharmaceutically acceptable carrier and as an active substance, the cell composition according to claim 26.

37. (currently amended) The cell composition according to claim 22, wherein said composition is derived from ~~and/or~~

~~included in~~ a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

38. (currently amended) The cell composition according to claim 23, wherein said composition is derived from ~~and/or included in~~ a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,
- from about 0.1 to about 20% of progenitor cells,
- from about 1 to about 50% of polynuclear cells, and
- from about 0.1 to about 20% of stem cells.

39. (currently amended) The cell composition according to claim 26, wherein said composition is derived from ~~and/or included in~~ a peripheral blood mononuclear cell composition containing:

- from about 10 to about 50% of monocytes,
- from about 10 to about 70% of lymphocytes,

- from about 0.1 to about 20% of progenitor cells,

- from about 1 to about 50% of polynuclear cells, and

- from about 0.1 to about 20% of stem cells.

40. (currently amended) The cell composition according to claim 32, wherein said medium ~~comprises cytokines and growth factors~~ contains at least one component selected from the group consisting of cytokines and growth factors.

41. (currently amended) The cell composition according to claim 33, wherein said medium ~~comprises cytokines and growth factors~~ contains at least one component selected from the group consisting of cytokines and growth factors.